|Krzysztof K³os, Robert Kruszewski, Katarzyna Wrotek|
Anaphylaxis is often associated with an IgE-dependent reaction. Therefore, therapy with anti-IgE monoclonal antibody (omalizumab) seems to be a valuable treatment option. It has already shown good results in management of atopic asthma. An active 32-year-old female patient with seasonal allergic rhinitis and severe uncontrolled bronchial asthma experienced eleven episodes of anaphylactic reactions requiring epinephrine injections from December 2005 till February 2007. In March 2006 she began treatment with omalizumab dosed at 300 mg/28 days. Though the patient continued to complain about the increased sleepiness and malaise for 1-2 days following each drug administration, the complete withdrawal of asthma symptoms was observed during the therapy. However, the medication did not prevent any further anaphylactic reactions. Skin prick tests were performed just before and 4 days after the sixth dose of anti-IgE (administered in July 2006), as well as in February 2007. They revealed no significant improvement when compared to the tests carried out at the beginning of the therapy. Skin prick testing was associated with tachycardia, blood pressure drop, pruritus, sneezing and cough. The presented case report suggests that Omalizumab might be less effective in prevention of recurrent anaphylactic reactions.
keywords: anafilaksja, omalizumab, anaphylaxis, omalizumab
pages: from 225 to 230
|estimated time of download (140 kB)|